# TVRD catalysts: Tvardi Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tvrd/catalysts

> Tvardi Therapeutics, Inc. (TVRD) has 1 upcoming catalyst. The next is the TTI-101 topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for TVRD?

Tvardi Therapeutics, Inc. (TVRD) has 1 upcoming catalyst. The next is the TTI-101 topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation." [Calendar and source filings](https://sec-api.dev/companies/tvrd/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126507, https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/tvrd/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Tvardi Therapeutics, Inc. |
| Ticker | TVRD (Nasdaq) |
| SEC CIK | 1346830 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tvrd |

## Cash runway

Cash $22.3M as of 2026-09-30; quarterly burn $6.4M; about 10.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-126508).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2023 | [TTI-101 trial start](https://sec-api.dev/pdufa/tti-101) | TVRD | suffering | completed | "In August 2023, we dosed the first patient in our ongoing 12-week REVERT IPF Phase 2 clinical trial for the treatment of patients suffering from IPF." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm)) |
| May 12, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2025 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_ex99-1.htm)) |
| 2H 2025 | [TTI-101 interim data readout](https://sec-api.dev/pdufa/tti-101) | TVRD |  | scheduled | "Preliminary topline data from the REVERTLIVER CANCER study is anticipated in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465924129596/tm2431150d1_ex99-1.htm)) |
| August 14, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2025 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm)) |
| August 14, 2025 | [TTI-101 primary completion](https://sec-api.dev/pdufa/tti-101) | TVRD | Idiopathic Pulmonary Fibrosis | completed | "NCT05671835 (Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Tvardi Therapeutics, Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05671835)) |
| Q4 2025 | [TTI-101 topline data readout](https://sec-api.dev/pdufa/tti-101) | TVRD | idiopathic pulmonary fibrosis | scheduled | "2 trial of TTI-101, for patients with idiopathic pulmonary fibrosis (IPF); topline data on track for Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm)) |
| November 13, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "Announces Third Quarter 2025 Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_ex99-1.htm)) |
| 1H 2026 | [Tvardi Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | scheduled | "We plan to report preliminary topline data from this clinical trial in the first half of 2026." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm)) |
| 1H 2026 | [TTI-101 interim data readout](https://sec-api.dev/pdufa/tti-101) | TVRD |  | scheduled | "We plan to report preliminary topline data from this clinical trial in the first half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465925035121/tm2512159d1_8k.htm)) |
| 1H 2026 | [Tvardi Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | scheduled | "The study is ongoing and Tvardi expects to report out topline data from this trial in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465925111289/tvrd-20250930x10q.htm)) |
| 1H 2026 | [TTI-101 topline data readout](https://sec-api.dev/pdufa/tti-101) | TVRD |  | scheduled | "A Phase 1 trial of TTI-109 in healthy volunteers to evaluate safety, tolerability, and pharmacokinetics, as well as bioequivalence to TTI-101, is ongoing and Tvardi expects to report out topline data from this trial in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465925111289/tvrd-20250930x10q.htm)) |
| March 31, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "31, 2026 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm)) |
| Q2 2026 | [TTI-109 interim data readout](https://sec-api.dev/pdufa/tti-109) | TVRD |  | scheduled | "Preliminary topline data from a healthy volunteer study of the company's next-generation STAT3 inhibitor, TTI-109, anticipated in the second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm)) |
| May 8, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2026 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm)) |
| Jun 2026 | [TTI-109 topline data readout](https://sec-api.dev/pdufa/tti-109) | TVRD |  | scheduled | "TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm)) |
| 2H 2026 | [Tvardi Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | scheduled | ""In parallel, we remain on track to report topline data from our ongoing Phase 2 REVERT LIVER CANCER trial in the second half of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm)) |
| 2H 2026 | [TTI-109 topline data readout](https://sec-api.dev/pdufa/tti-109) | TVRD |  | scheduled | "The ongoing Phase 1b/2 REVERT LIVER CANCER trial will report topline results in the second half of 2026 to allow the data additional time to mature." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm)) |
| Jul 2026 | [Tvardi Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed, positive | "We reported positive topline data from this trial in July 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/tvrd-20260630x10q.htm)) |
| 2H 2026 | [TTI-101 interim data readout](https://sec-api.dev/pdufa/tti-101) | TVRD |  | scheduled | "Preliminary topline data from the company's ongoing REVERT LIVER CANCER Phase 1b/2 clinical trial of TTI-101, anticipated in the second half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm)) |
| August 14, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2026 - Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its &filig;nancial and operating results for the second quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_ex99-1.htm)) |
| Q4 2026 | [TTI-101 topline data readout](https://sec-api.dev/pdufa/tti-101) | TVRD |  | scheduled | "We expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial in patients with HCC in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/tvrd-20260630x10q.htm)) |
| November 13, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "Tvardi Therapeutics Announces Third Quarter 2026 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm)) |
| Q1 2027 | [TTI-101 topline data readout](https://sec-api.dev/pdufa/tti-101) | TVRD | HCC early | scheduled | "The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm)) |

## Drugs

- [TTI-101](https://sec-api.dev/pdufa/tti-101): idiopathic pulmonary fibrosis, suffering, hcc early
- [TTI-109](https://sec-api.dev/pdufa/tti-109): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tvrd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TVRD catalysts: Tvardi Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tvrd/catalysts

```bibtex
@misc{secapidev_companies_tvrd_catalysts_20261116,
  title        = {TVRD catalysts: Tvardi Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tvrd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tvrd_catalysts_20261116","title":"TVRD catalysts: Tvardi Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tvrd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
